Raymond James Initiates Coverage on Magenta Therapeutics (MGTA)
Investment analysts at Raymond James began coverage on shares of Magenta Therapeutics (NASDAQ:MGTA) in a research note issued to investors on Thursday, The Fly reports. The firm set an “outperform” rating on the stock.
Several other equities research analysts have also issued reports on the company. ValuEngine lowered Magenta Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. Zacks Investment Research lowered Magenta Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $19.33.
Shares of MGTA stock traded down $0.56 on Thursday, hitting $13.71. 99,774 shares of the stock traded hands, compared to its average volume of 168,985. Magenta Therapeutics has a 1-year low of $5.31 and a 1-year high of $17.55.
About Magenta Therapeutics
Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.
Further Reading: Municipal Bonds
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.